These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25370902)

  • 1. Association of CYP3A4/5 genotypes and expression with the survival of patients with neuroblastoma.
    Darwish MH; Farah RA; Farhat GN; Torbey PH; Ghandour FA; Bejjani-Doueihy NA; Dhaini HR
    Mol Med Rep; 2015 Feb; 11(2):1462-8. PubMed ID: 25370902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in genes encoding drug metabolizing enzymes and their influence on the outcome of children with neuroblastoma.
    Ashton LJ; Murray JE; Haber M; Marshall GM; Ashley DM; Norris MD
    Pharmacogenet Genomics; 2007 Sep; 17(9):709-17. PubMed ID: 17700360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
    Vo KT; Matthay KK; Neuhaus J; London WB; Hero B; Ambros PF; Nakagawara A; Miniati D; Wheeler K; Pearson AD; Cohn SL; DuBois SG
    J Clin Oncol; 2014 Oct; 32(28):3169-76. PubMed ID: 25154816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
    Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
    Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.
    Perfumo C; Parodi S; Mazzocco K; Defferrari R; Inga A; Scarrà GB; Ghiorzo P; Haupt R; Tonini GP; Fronza G
    Pediatr Blood Cancer; 2009 Oct; 53(4):576-83. PubMed ID: 19526525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
    Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
    J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
    Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
    J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of MYCN expression in human neuroblastoma cells.
    Jacobs JF; van Bokhoven H; van Leeuwen FN; Hulsbergen-van de Kaa CA; de Vries IJ; Adema GJ; Hoogerbrugge PM; de Brouwer AP
    BMC Cancer; 2009 Jul; 9():239. PubMed ID: 19615087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
    de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
    Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
    Rubie H; De Bernardi B; Gerrard M; Canete A; Ladenstein R; Couturier J; Ambros P; Munzer C; Pearson AD; Garaventa A; Brock P; Castel V; Valteau-Couanet D; Holmes K; Di Cataldo A; Brichard B; Mosseri V; Marquez C; Plantaz D; Boni L; Michon J
    J Clin Oncol; 2011 Feb; 29(4):449-55. PubMed ID: 21172879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management and outcome of stage 3 neuroblastoma.
    Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
    Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
    Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
    Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma.
    Zhong ZY; Shi BJ; Zhou H; Wang WB
    J Int Med Res; 2018 Mar; 46(3):1209-1220. PubMed ID: 29322842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of microRNA 21 With Biological Features and Prognosis of Neuroblastoma.
    Zhou Y; Sheng B
    Cancer Control; 2016 Jan; 23(1):78-84. PubMed ID: 27009461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
    Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.